18F-Clofarabine PET/CT in Imaging Cancer Patients before and after Interventions

This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly expressed in activated immune cells, making them light up during PET/CT scans. Doctors also want to know how 18F-clofarabine is distributed throughout the body before and after treatment with immunotherapies.

Additional locations may be listed on ClinicalTrials.gov for NCT02888301.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhaseNo phase specified

Trial Typebasic science

Lead OrganizationUCLA / Jonsson Comprehensive Cancer Center

Principal InvestigatorMartin Allen-Auerbach

• Primary ID15-000246
• Secondary IDsNCI-2016-00210
• ClinicalTrials.gov IDNCT02888301